Wang Yaru, Ma Zhuolin, Kan Pengcheng, Zhang Biao
Graduate School, Tianjin Medical University, Tianjin, PR China.
Clinical Laboratory, Tianjin Key Laboratory of Cerebral Vascular and Neurodegenerative Diseases, Tianjin Neurosurgical Institute, Tianjin Huanhu Hospital, Tianjin, PR China.
J Stroke Cerebrovasc Dis. 2017 May;26(5):1055-1060. doi: 10.1016/j.jstrokecerebrovasdis.2016.12.019. Epub 2017 Jan 19.
Circulating miRNAs have been demonstrated as biomarkers for a number of diseases. In the present study, we aimed to compare the serum levels of the miRNA-221-3p, miRNA-382-5p, and miRNA-4271 between ischemic stroke and healthy control subjects and explore the potential roles as noninvasive biomarkers in the diagnosis of ischemic stroke.
Seventy-eight patients with ischemic stroke (60 ± 10.47 years old) and 39 healthy control subjects (61 ± 5.14 years old), age and sex matched, were recruited into the present study. The circulating miRNA levels were determined by quantitative real-time polymerase chain reaction using miRNA qPCR Assay Kit (CW Biotech, Beijing, China). Receiver operating characteristic (ROC) curves were analyzed using the SPSS software package (version 17) (SPSS Inc., Chicago, IL).
Circulating serum miRNA-221-3p and miRNA-382-5p levels were significantly lower in patients with ischemic stroke compared to healthy control subjects, whereas there was no significant difference in the serum levels of miRNA-4271 between the stroke patients and healthy controls (P > .05). ROC curves revealed the areas under the curve for circulating miRNA-221-3p, miRNA-382-5p, and miRNA-4271 to be .8106, .7483, and .6317 in ischemic stroke patients compared with healthy volunteers, respectively. There were no correlations between circulating miRNAs and laboratory determinations except that the levels of circulating miRNA-4271 were positively correlated with glucose (r = .274, P = .031).
Our findings suggest that serum circulating miRNA-221-3p and miRNA-382-5p might be used as potential noninvasive biomarkers for the diagnosis of ischemic stroke.
循环miRNA已被证明是多种疾病的生物标志物。在本研究中,我们旨在比较缺血性中风患者与健康对照者血清中miRNA-221-3p、miRNA-382-5p和miRNA-4271的水平,并探讨其作为缺血性中风诊断中非侵入性生物标志物的潜在作用。
本研究纳入78例缺血性中风患者(年龄60±10.47岁)和39例健康对照者(年龄61±5.14岁),年龄和性别相匹配。使用miRNA qPCR检测试剂盒(中国北京康为世纪生物科技有限公司)通过定量实时聚合酶链反应测定循环miRNA水平。使用SPSS软件包(版本17)(美国伊利诺伊州芝加哥市SPSS公司)分析受试者工作特征(ROC)曲线。
与健康对照者相比,缺血性中风患者循环血清miRNA-221-3p和miRNA-382-5p水平显著降低,而中风患者与健康对照者血清miRNA-4271水平无显著差异(P>0.05)。ROC曲线显示,与健康志愿者相比,缺血性中风患者循环miRNA-221-3p、miRNA-382-5p和miRNA-4271的曲线下面积分别为0.8106、0.7483和0.6317。循环miRNA与实验室检测指标之间无相关性,仅循环miRNA-4271水平与血糖呈正相关(r = 0.274,P = 0.031)。
我们的研究结果表明,血清循环miRNA-221-3p和miRNA-382-5p可能作为缺血性中风诊断的潜在非侵入性生物标志物。